ArticlePediatrics2021
Trends in HPV Vaccination Initiation and Completion Within Ages 9-12 Years: 2008-2018.
Article in Pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 61 citations in OpenAlex.
- Trial
- Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10.Human vaccines & immunotherapeutics · 2023Trial
- Assessing HPV Vaccination Trends and Their Alignment with Evolving Recommendations.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Revealing the Crucial Role of Healthcare Providers in HPV Vaccine Uptake in Filipino American Adolescents: Insights from the National Immunization Survey-Teen, 2015-2019.Journal of racial and ethnic health disparities · 2025Article
- Healthcare provider perspectives on HPV vaccinations at ages 9-10 in the United States.Human vaccines & immunotherapeutics · 2025Article
- HPV vaccination in community health organizations: what is going right and how can it be replicated?Cancer causes & control : CCC · 2025Observational
- State-level disparities in cervical cancer prevention and outcomes in the United States: a modeling study.Journal of the National Cancer Institute · 2025Article
- Pediatric providers' views on participating in an HPV Vaccine Quality Improvement Intervention: a qualitative analysis.BMC pediatrics · 2024Article
- State-level disparities in cervical cancer prevention and outcomes in the U.S.: A modeling study.medRxiv : the preprint server for health sciences · 2024Article
- Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea.Cancer research and treatment · 2024Article
- Barriers to the assessment and recommendation of HPV vaccination among healthcare providers in Texas.Vaccine: X · 2024Article
- Article
- Vaccination Effectiveness against Human Papillomavirus in Kazakhstan.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The association of initiating HPV vaccination at ages 9-10 years and up-to-date status among adolescents ages 13-17 years, 2016-2020.Human vaccines & immunotherapeutics · 2023Article
- Human papillomavirus vaccination at the first opportunity: An overview.Human vaccines & immunotherapeutics · 2023Review
- HPV vaccine recommendations by age: A survey of providers in federally qualified health centers.Human vaccines & immunotherapeutics · 2023Article
- Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?Human vaccines & immunotherapeutics · 2023Article
- Age nine is possible: Improving age 9 HPV initiation through a national quality improvement initiative during the COVID-19 pandemic.Human vaccines & immunotherapeutics · 2023Article
- Mothers' perceptions and attitudes about HPV vaccination initiation among 9- and 10-year-olds.Human vaccines & immunotherapeutics · 2023Article
- Assessing Barriers to Human Papillomavirus (HPV) Vaccination in At-Risk Rural Communities of Western North Carolina, United States.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesRoutine human papillomavirus (HPV) vaccination is recommended at ages 11 to 12 years and may be initiated as early as 9 years of age.
methodsData were derived from the National Immunization Survey-Teen, spanning 2008-2018. Using health care provider-verified vaccination histories, we examined trends in human papillomavirus vaccination up-to-date (HPV-UTD) rates within ages 9 to 12 years. Furthermore, we assessed vaccination status by sociodemographic factors and US state of residence.
resultsOverall, amid evidence of recent stagnation, HPV vaccination between ages 9 to 12 increased over the years. Initiation rates rose from 17.3% in 2008 to 62.8% in 2018, and HPV-UTD rates rose from 13.5% in 2011 to 32.8% in 2018. After the inception of gender-neutral HPV vaccination, HPV-UTD rates between 2011 and 2018 rose by 31.9% among boys and only 6.6% among girls. For most of the study period, non-Hispanic Black and Hispanic individuals had higher rates of initiation and HPV-UTD than non-Hispanic white individuals. In 2018, vaccination initiation rates exceeded 70% in several states; however, HPV-UTD rates in most US states were <50%, excluding Rhode Island (61.6%), Colorado (58.7%), Hawaii (53.5%), District of Columbia (53.2%), and Ohio (50%).
conclusionsHPV vaccination within ages 9 to 12 years is suboptimal. To leverage the substantial benefits of HPV vaccination within this age range, it is imperative that conscious efforts are taken at the national and state levels to promote HPV vaccination for this age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.